01 Shift toward Advanced CBD Delivery SystemsThe cannabidiol market analysis shows that CBD’s poor water solubility is directing research toward advanced delivery systems, including solid dispersions and self-nanoemulsifying formulations. These technologies aim to improve dissolution and oral absorption, supporting the development of more consistent formulations for pharmaceutical applications. A 2025 study published in AAPS PharmSciTech reported that polymer-based CBD solid dispersions improved the dissolution rate by up to 4.75 times in laboratory testing.
02 Shift toward Pharmaceutical-Grade CBD FormulationsThe need for reliable therapeutic products is directing development toward purified CBD, controlled dosing, and rigorous manufacturing standards. This transition supports consistent product quality and clinically validated applications while reducing reliance on unverified health claims. The U.S. Food and Drug Administration (FDA) has approved Epidiolex, a purified CBD oral solution, for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients aged one year and older.
01 Demand for CBD Personal Care Products and Quality-Control Services Drive MarketQuality concerns surrounding CBD products encourage manufacturers to use laboratory testing to verify cannabinoid content, purity, and potential contaminants. The U.S. Food and Drug Administration (FDA) has reported that testing of some CBD products found discrepancies between their actual and claimed CBD levels, highlighting the need for reliable quality checks. For example, independent laboratories can test CBD oils and cosmetic ingredients for cannabinoid concentration and unwanted substances before commercial distribution. These testing services help manufacturers improve product consistency and meet applicable safety and labeling requirements, creating opportunities for specialized laboratories and quality-control providers.Consumer interest in specialized skincare products encourages personal care brands to explore CBD in creams, balms, and skin-conditioning formulations. The European Commission’s Scientific Committee on Consumer Safety concluded in April 2026 that CBD was considered safe at concentrations up to 0.19% in dermal cosmetic products, based on the available data and the assessment’s stated limitations. This assessment gives cosmetic manufacturers a relevant safety reference when evaluating CBD formulations for applicable European markets. For example, skincare brands may develop CBD-containing moisturizers and body creams while assessing ingredient concentration and product safety. Such formulation opportunities can create demand for suitable CBD ingredients and specialized cosmetic manufacturing services.
01 Limited Insurance Coverage and High Product Testing and Regulatory Compliance Costs Restrain Market ExpansionLimited insurance coverage for CBD-based treatments restrains the Cannabidiol (CBD) Market because patients may need to pay out of pocket when their prescribed products are not covered by insurance plans. According to the National Association of Insurance Commissioners (NAIC), conflicting cannabis laws and evolving regulations continue to discourage insurers from offering broad, affordable coverage in this sector. These coverage limitations can increase treatment costs for patients and restrict access to prescription CBD products and other CBD-based therapies. High product testing and regulatory compliance costs constrain the Cannabidiol (CBD) Market because manufacturers need to verify CBD concentrations, assess contaminants, and meet applicable product safety and labeling requirements. The U.S. Food and Drug Administration (FDA) has approved only one CBD-based prescription drug, Epidiolex, while other CBD products have not received FDA approval as drugs. These requirements can increase laboratory testing and compliance expenses, complicate product launches, and create additional barriers for smaller manufacturers entering regulated markets.
01 CBD Research Partnerships and Compliant Food Ingredient Applications Create New Revenue Opportunities Offers Growth OpportunitiesFood manufacturers, beverage companies, and specialty ingredient suppliers can explore compliant hemp-derived ingredients for functional food formulations in markets where regulations permit their use. The U.S. FDA has evaluated hemp seed oil, hulled hemp seeds, and hemp seed protein powder for specified food uses, although CBD itself cannot currently be lawfully added to conventional foods in the United States. Regulatory-compliant ingredient supply, product development partnerships, and licensing agreements offer potential revenue avenues in eligible markets.Pharmaceutical companies, biotechnology firms, and clinical research institutions can collaborate to evaluate CBD for specific medical applications and develop evidence-based treatments. The U.S. FDA has approved Epidiolex, a purified CBD medicine, for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex, demonstrating the potential of regulated CBD-based drug development. Companies such as Jazz Pharmaceuticals, associated with Epidiolex, can participate in this space through clinical research, drug development, and licensing partnerships.
September 2025 CV Sciences expanded its PlusCBD™ product portfolio with new hemp-derived CBD formulations focused on wellness applications, strengthening its position in the cannabinoid consumer products segment.
July 2025 Canopy Growth expanded its CBD and wellness product portfolio by advancing cannabinoid-based consumer products and strengthening brand initiatives across regulated markets.
June 2025 Tilray Brands expanded its cannabinoid wellness portfolio by advancing hemp-derived CBD product offerings and strengthening its presence in consumer wellness markets through product development initiatives.
May 2025 Charlotte’s Web expanded its cannabidiol (CBD) product portfolio by introducing new hemp-derived wellness products and strengthening distribution initiatives across retail and online channels.